The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Poly(ADP ribose) polymerase (PARP) inhibition in peripheral blood lymphocytes (PBLs): Does it reflect PARP inhibition in tumor?
D. R. Shalinsky
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer (B)
D. D. Wang
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
K. A. Kern
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
P. English
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
N. J. Curtin
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer
Other Remuneration - Pfizer
R. Plummer
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer
Other Remuneration - Pfizer